Agència d’Informació Avaluació I Qualitat en Salut (2011). Guía de práctica clínica sobre trastorno límite de la personalidad. Retrieved from https://consaludmental.org/publicaciones/GPCTrastornoLimitePersonalidad.pdf.

American Psychiatric Association. (2001). Practice guideline for the treatment of patients with borderline personality disorder. The American Journal of Psychiatry. 158(Suppl10):1–52.

Amminger P, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, Nelson B, Thompson A, McGorry P, Yung A & Schäfer M. (2013) Omega-3 Fatty Acid Supplementation in Adolescents With Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double-Blind, Randomized Controlled Trial. CanJPsychiatry. 58(7):402–408.

Argent S & Hill S (2014). The novel use of clozapine in an adolescent with borderline personality disorder. Ther Adv Psychopharmacol, 4(4):149-55. doi: 10.1177/2045125314532488.

Barnes RJ (1977). Mesoridazine in personality disorders – a controlled trial in adolescent patients. Diseases of the nervous system, 38:258-264.

Caihol L., Jeannot M, Rodgers R, Guelfi JD, Perez-Diaz F, Pham-Scottez A, Corcos M & Speranza M (2013). Borderline personality disorder and mental healthcare service use among adolescents. J Pers Disord, 27:252-259. Doi:10.1521/pedi.2013.27.2.252.

CBO (2008). Multidisciplinaire Richtlijn Persoonlijkheidsstoornissen. Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Trimbos instituut, Utrecht.

Chiesa M, Wright M & Leger D (2004). Psychotropic medication and the therapeutic community: a survey of prescribing practices for severe personality disorder. Therapeutic Communities, 25(2):131-144.

Golubchik P, Sever J, Zalsman G & Weizman A (2008). Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. International Clinical Psychopharmacology, 23:228–231.

GGZ Zorgstandaard Persoonlijkheidsstoornissen (2017). AKWA, Utrecht. https://www.ggzstandaarden.nl/zorgstandaarden/persoonlijkheidsstoornissen-zorgstandaard-2017/introductie.

Ingenhoven T (2015). Pharmacotherapy for borderline patients: business as usual or by default? Journal of Clinical Psychiatry, 76 (4):522-523.

Ingenhoven T & Rinne T (2018). Farmacotherapie bij borderline-persoonlijkheidsstoornis: update 2018. Aanvullend hoofdstuk in https://www.leeromgeving-boom.tijdstroom.nl. In: Theo Ingenhoven, Han Berghuis, Sjoerd Colijn & Rien Van. Handboek persoonlijkheidsstoornissen. Utrecht, De Tijdstroom.

Kutcher S, Papatheodorou G, Reiter S & Gardner D (1995). The Successful Pharmacological Treatment of Adolescents and Young Adults with Borderline Personality Disorder: A Preliminary Open Trial of Flupenthixol. J Psychiatr Neurosci, 20(2):113-118.

Midgley, N., Holmes, J., Parkinson, S. e.a. (2014). “Just like talking to someone about like shit in your life and stuff, and they help you”: Hopes and expectations for therapy among depressed adolescents. Psychotherapy Research.

National Collaborating Centre for Mental Health (UK). Borderline Personality Disorder: Treatment and Management. Leicester (UK): British Psychological Society; 2009. PMID: 21796831

National Health and Medical Research Council (2013). Clinical Practice Guideline for the management of Borderline Personality DisorderRetrieved form https://www.nhmrc.gov.au/about-us/publications/clinical-practice-guideline-borderline-personality-disorder.

National Institute for Health and Care Excellence (2009). Borderline personality disorder: treatment and management (NICE clinical guideline 78). Retrieved from www.nice.org.uk/CG78.

Podobnik J, Foller Podobnik I, Grgic N, Marcinko D & Pivac N (2012). The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents. Psychopharmacology, 220:639–641. DOI 10.1007/s00213-011-2607-7.

Scalzo F, Hulbert CA, Betts JK, Cotton SM, Chanen AM. Substance Use in Youth With Borderline Personality Disorder. J Pers Disord. 2018 Oct;32(5):603-617.

Sundhedsstyrelsen (2015). Behandling af emotional ustabil personlighedsstruktur, borderline type. Retrieved from https://www.sst.dk/da/udgivelser/2019/nkr-behandling-af-emotionel-ustabil-personlighedsstruktur-borderline-type.

Wöckel L, Goth K, Zepf FD, Matic N, Holtmann M, Herpertz-Dahlmann B & Poustka
F (2010). [Psychopharmacotherapy improves psychosocial functioning in adolescents with
borderline personality disorder] [Article in German]. Prax Kinderpsychol Kinderpsychiatr, 59(4):282-301. DOI: 10.13109/prkk.2010.59.4.282.

Farmacotherapeutisch Kompas 2020